Pasithea Therapeutics (KTTA) Stock Price

Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics.